Similarly, the presence of PD-L1+ immune cells in DCIS has been reported to be associated with high TIL infiltration, younger patient age, ER negativity, and HER2 positivity in previous studies [16, 20–22]. The gene discussed is ESR1; the disease is ductal breast carcinoma in situ.